|
|
||||||||
Ann Thorac Surg 2006;82:2067-2071
© 2006 The Society of Thoracic Surgeons
a Department of Cardiothoracic Surgery, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv
c Catheterization Laboratory, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv
b Center for Quality, Safety and Data, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem
d Departments of Cardiology and Cardiac Surgery, Assuta Medical Center, Petach Tikva, Israel
Accepted for publication June 15, 2006.
* Address correspondence to Dr Mohr, Department of Cardiothoracic Surgery, Tel Aviv Sourasky Medical Center, 6 Weizman St, Tel Aviv 64239, Israel. (Email: marion{at}tasmc.health.gov.il).
| Adult cardiac surgery:
The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS member or an individual non-member subscription to the journal.
|
| Abstract |
|---|
|
|
|---|
METHODS: From May 2002 to December 2003, 376 consecutive patients underwent myocardial revascularization of the LAD, 272 by Cypher and 104 by MIDCAB. After matching for age, sex, and extent of coronary artery disease, two groups of 83 patients each were used to compare the two revascularization modalities. The groups were similar; however, ejection fraction of less than 0.35 was more prevalent in the MIDCAB group and prior percutaneous coronary intervention in the Cypher group.
RESULTS: Thirty-day mortality was 1.1% in the MIDCAB and 0% in the Cypher group. Mean follow-up was 22.5 months. Two late cardiac deaths occurred in the MIDCAB group and one in the Cypher group (p = NS). Angina returned in 35% of the Cypher group and in 8.4% of the MIDCAB group (p < 0.001). There were 14 (16.8%) reinterventions in the Cypher compared with three (3.6%) in the surgical group (p = 0.005). Cox proportional hazard model showed that assignment to the Cypher group was the only independent predictor of reangina (hazard ratio [HR], 6.17, 95% confidence interval [CI], 2.46 to 15.4). Treatment with Cypher was also an independent predictor of reintervention (HR 8.26, 95% CI, 1.68 to 40).
CONCLUSIONS: Despite improved results of percutaneous interventions with Cypher to the LAD, mid-term clinical outcome of patients treated with MIDCAB was better.
In patients with multivessel disease, surgical revascularization of the left anterior descending (LAD) with the internal thoracic artery (ITA) is still the only proven method of improving event-free survival [1, 2]. The proximal LAD is a challenging area for percutaneous interventions (PCI) because of concern for injury to the left main artery or occlusion of major side branches [3]. Therefore, coronary artery bypass grafting (CABG) is often considered, and sometimes performed, even in patients with single-vessel disease.
Considerable reduction of restenosis and reintervention rates was recently reported with the introduction of drug-eluting stents [4, 5]. In a recent report of 459 patients with single LAD stenosis, drug-eluting stents significantly decreased restenosis and reintervention rates compared with bare-metal stents [6].
Most patients with single-vessel disease involving the proximal LAD referred for bypass surgery in our institution are operated on using the minimally invasive direct coronary artery bypass (MIDCAB) technique. We therefore decided to compare their outcome with that of matched patients who underwent PCI with drug-eluting stents.
| Patients and Methods |
|---|
|
|
|---|
|
|
During the study period, selection criteria for surgery versus PCI were mainly technical. In principle, there was a preference to refer patients for surgery for the following reasons:
All MIDCAB patients were operated on without extracorporeal circulation, and all surgical procedures included implantation of a single graft (left ITA) to the LAD. The MIDCAB technique was described in detail by Diegeler and colleagues [7]. In brief, a limited left anterolateral thoracotomy was performed through the fourth intercostal space. The internal thoracic artery was harvested under direct vision. After administration of heparin (200 U/kg), the activated clotting time was kept on an elevated level of more than 400 seconds by repeat application of heparin, if needed.
The internal thoracic artery was divided distally. Local immobilization of the anastomotic site was achieved with mechanical stabilizers. The anastomosis was performed with the use of one running 7-0 polypropylene suture on the beating heart. Protamine was applied to partially neutralize the dose of heparin. Wounds were closed in a standard fashion.
In the PCI group, stent implantation was performed after balloon angioplasty dilatation. All patients received aspirin (325 mg daily) before and after the procedure and a 300-mg loading dose of clopidogrel the day before the procedure and 75 mg daily for at least 3 months thereafter. During the procedure all patients were treated intravenously with heparin. In most patients, only one Cypher stent was used for the LAD; however, more than one was used if required (eg, long lesion, dissection). In 2 patients with bifurcation lesion, PCI included treatment of two vessels (LAD and diagonal branch) (Table 1).
Acute myocardial infarction (within the previous 48 hours), poor ejection fraction (0.25), left main disease, calcification, or thrombus within the LAD, long lesions (>30 mm) and bifurcation lesions were major criteria for exclusion of patients from the group treated with stents to the LAD. Patients with diabetes mellitus or ostial LAD lesions were not excluded. All patients in the MIDCAB group were treated postoperatively with an intravenous infusion of isosorbide dinitrate (Isoket 420 mg/h) during the first postoperative 2448 hours [8].
Statistical Analysis
Data are expressed as mean ± SD or proportions, as appropriate. The two groups were matched for age, sex, and extent of coronary artery disease. The
2 test and Fisher exact test were used in the stepwise method to compare discrete variables. The Cox proportional hazard model was used to evaluate risk factors for early return of angina and reintervention. Hazard ratio (HR) and 95% confidence interval (CI) were given. Survival Postoperative survival free of angina, major adverse cardiovascular event (MACE), and reintervention are expressed by the Kaplan-Meier method, and comparison between groups was made by the log-rank test. All analyses were performed by SPSS 12 software (SPSS Inc, Chicago, IL).
| Results |
|---|
|
|
|---|
Reasons for performing the MIDCAB procedure included age older than 80 years (n = 8), chronic renal failure (n = 3), malignancy (n = 3), advanced peripheral vascular disease (n = 3), morbid obesity (n = 3), chronic obstructive pulmonary disease (n = 2), and neurologic incapacity after stroke (n = 2). The desire by cardiologists and patients to minimize surgical trauma was the only indication for referral to MIDCAB in the remaining patients with two-vessel or three-vessel disease.
Thirty-day mortality was 1.1% in the MIDCAB group and 0% in the Cypher group. Mean follow-up was 22.5 months (range, 6 to 33 months). One late death occurred in the Cypher group and four in the MIDCAB group (p = 0.173); however, only two of the four deaths were cardiac-related. The 2-year actuarial survival (Kaplan-Meier) was not different statistically (98% versus 93% in the Cypher versus MIDCAB group, p = 0.11). Angina returned in 29 patients (35%) of the Cypher group compared with 7 (8.4%) in the MIDCAB group (p < 0.001). There were 14 reinterventions (16.8%) in the Cypher group: 11 coronary angioplasties and three surgical interventions. There were three (3.6%) reinterventions (all PCI) in the surgical group (p = 0.005, Cypher versus MIDCAB). Seven patients in the Cypher group underwent reintervention to the LAD, compared with only 1 in the MIDCAB group (p = 0.029). Three patients of the Cypher and 1 of the MIDCAB group had more than one reintervention during the follow-up period.
The prevalence of reinterventions was higher in the PCI group and in the surgical group among patients with multivessel disease (20% and 5%, respectively) compared with 7% and 0%, respectively, in patients with single-vessel disease; however, the difference did not reach statistical significance (p = 0.109 and p = 0.229, respectively).
During the follow-up period, there were two myocardial infarctions in the MIDCAB group and five in the Cypher group (p = NS). The occurrence of MACE, consisting of cardiac mortality, myocardial infarction, or reintervention, was significantly higher in the Cypher group at 20.5% (17 events) versus 7.2% (6 events) in the surgical group (p = 0.013). Independent predictors of MACE (Cox analysis) were assignment to the Cypher group (HR, 4.1; 95% CI, 1.26 to 13.16), multivessel disease (HR, 4.3; 95% CI, 1.44 to 13.16), and prior PCI (HR, 4.36; 95% CI, 1.28 to 14.90).
Two-year angina-free survival (Kaplan-Meier) of the MIDCAB patients was 87.4% compared with 57% in the PCI patients (p = 0.002, long-rank test) (Fig 1). The difference in 2-year reintervention-free survival did not reach statistical significance (91.6% versus 81.7%, p = 0.118 log-rank test). However, the difference in MACE-free survival was significant (94.7% versus 79%, p = 0.007) (Fig 2).
|
|
| Comment |
|---|
|
|
|---|
Several recently published reports comparing MIDCAB with stents have documented superior clinical and angiographic outcome of surgical treatment over stenting in LAD revascularization [17, 20, 21]. However, MIDCAB in these reports was compared with PCI of the LAD with bare-metal stents. In our study, all PCI patients were treated with Cypher drug-eluting stents.
To control for differences between groups in preoperative characteristics, treatment groups were compared only after matching for age, sex and extent of coronary artery disease, and the Cox proportional hazard model was used to define independent predictors of adverse outcome events like reangina, reintervention, and MACE. After a mean follow-up of almost 2 years, which is long enough for the development of in-stent restenosis [22], survival was similar; however, less than 60% of the Cypher patients were angina-free, and 11 (13.2%) required one or two reinterventions. Target vessel (LAD) reintervention in the Cypher-treated group was 8.4% (7 patients) compared with 1.2% (1 patient) in the MIDCAB group. After a mean follow-up period of almost 2 years, only 79% of the Cypher group was free of MACE compared with 94% of the MIDCAB group.
Despite the relatively high incidence of incomplete revascularization in both groups, the only independent predictor for angina recurrence and reintervention in our study was assignment to the Cypher group. Assignment to the Cypher group was not the only predictor of MACE, however. Other predictors were incomplete revascularization and prior PCI.
Important covariates (mainly technical), such as vessel diameter or lesion length, were not included in the analysis. These variables, which are less important in the surgical group, may affect restenosis, reangina, and reintervention in the PCI group. Owing to the exclusion criteria for drug-eluting stents, only type A and type B lesions were addressed by PCI in this study. If one would focus on the entire patient population with all types of LAD lesions, the results might have been more definitive in favor of the surgical group. Larger prospective multicenter studies are required to determine the effect of lesion morphology in patients selected for PCI or surgery in this evolving era of drug-eluting stents.
Another limitation of this study is the relatively limited mean follow-up period of 22 months. Evidence is growing that drug-eluting stents may develop delayed thrombosis related to delayed endothelialization, hypersensitivity to the stent polymer, or discontinuation of antiplatelet treatment [23, 24]. Longer follow-up is therefore required.
In conclusion, mid-term clinical outcome of MIDCAB patients was better than that of patients treated with percutaneous intervention with a Cypher drug-eluting stent to the LAD. The reangina and reintervention gap [24] between surgery and percutaneous interventions may further be reduced by better patient selection and avoiding lone PCI to the LAD in patients with multi-vessel disease or patients with prior PCI to this vessel.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Thiele, P. Neumann-Schniedewind, S. Jacobs, E. Boudriot, T. Walther, F.-W. Mohr, G. Schuler, and V. Falk Randomized Comparison of Minimally Invasive Direct Coronary Artery Bypass Surgery Versus Sirolimus-Eluting Stenting in Isolated Proximal Left Anterior Descending Coronary Artery Stenosis J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2324 - 2331. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-J. Goy, U. Kaufmann, M. Hurni, S. Cook, F. Versaci, P. Ruchat, O. Bertel, M. Pieper, B. Meier, L. Chiarello, et al. 10-Year Follow-Up of a Prospective Randomized Trial Comparing Bare-Metal Stenting With Internal Mammary Artery Grafting for Proximal, Isolated De Novo Left Anterior Coronary Artery Stenosis: The SIMA (Stenting versus Internal Mammary Artery grafting) Trial J. Am. Coll. Cardiol., September 2, 2008; 52(10): 815 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Giglio, A. Dell'Amore, T. Aquino, S. Calvi, M. Calli, C. Marri, F. Boni, and M. Lamarra Minimally invasive coronary artery bypass grafting using the inferior J-shaped ministernotomy in high-risk patients Interactive CardioVascular and Thoracic Surgery, June 1, 2008; 7(3): 402 - 405. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jacobs, D. Holzhey, H. Stein, F. W. Mohr, and V. Falk Catheter-Based Endoscopic Bypass Grafting: An Experimental Feasibility Study Ann. Thorac. Surg., November 1, 2007; 84(5): 1724 - 1727. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Ott Invited commentary Ann. Thorac. Surg., November 1, 2007; 84(5): 1727 - 1728. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |